Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MDUFMA II Should Address Pre-IDE Process, Cycle Goals – Stakeholders

This article was originally published in The Gray Sheet

Executive Summary

FDA should work to improve the process by which companies and the agency negotiate clinical trial designs, several participants argued at the third annual MDUFMA stakeholder meeting Nov. 17
Advertisement

Related Content

People In Brief
CDRH “Innovation Initiative” Highlights Efforts To Speed Premarket Process
Industry Favors Predictability Over Speed In Next Round Of MDUFMA
Bioabsorbable Stents Raise New Concerns For Investigators And Regulators
More Needs To Be Done To Accelerate Device Reviews – von Eschenbach
MDUMFA II Discussions May Touch On Need For FDA Guidance, Transparency
Device Center Director Schultz Floats User Fees For Postmarket Efforts
Regulatory News In Brief
Funding Limits Will Force Choices At Device Evaluation Office – Tillman
Funding Limits Will Force Choices At Device Evaluation Office – Tillman
Advertisement
UsernamePublicRestriction

Register

MT022924

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel